Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi is scrapping plans for an eczema drug derived from its billion-dollar Kymab acquisition following a strategic pipeline review.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Sanofi abandoned plans to seek approval for amlitelimab, an OX40L antibody for atopic dermatitis originating from its Kymab buyout. The company shelved the drug and scrapped trials following a pipeline review under a new CEO.
Epilogue added 93d ago, after coverage quieted.
The brief
Sanofi has announced the decision to abandon its plans to seek regulatory approval for a specific drug intended to treat eczema, also known as atopic dermatitis. This medication, identified as amlitelimab, was developed as part of the company's acquisition of Kymab. According to reports from BioSpace and Fierce Biotech, the drug is an OX40L antibody. The decision to shelf this particular candidate comes as part of a broader strategic shift within the company's pharmaceutical development goals, effectively halting the trials for the drug in the treatment of atopic dermatitis. Coverage of this development is widespread across industry-specific and general financial news outlets. Endpoints News reports that Sanofi has officially nixed the Kymab-originated OX40L antibody for use in eczema.
FirstWord Pharma specifies that amlitelimab was shelved following a comprehensive review of the company's pipeline. The Wall Street Journal highlights that this pivot is occurring amid a wider review of the corporate pipeline conducted under the leadership of Sanofi's new CEO. These outlets collectively emphasize the sudden cessation of the drug's path toward market approval. To understand the significance of this move, it is necessary to look at the financial stakes involved in the original acquisition. Fierce Biotech and BioSpace note that the Kymab buyout was valued at approximately $1.1 billion, though BioSpace describes the investment as a $1.4 billion bet. The discontinuation of amlitelimab for atopic dermatitis represents a setback for this specific investment.
The drug was expected to be a key outcome of the Kymab deal, and its removal from the pipeline indicates a change in how Sanofi is prioritizing its acquired assets under its current executive leadership. Looking forward, the focus remains on the results of the ongoing pipeline review led by the new CEO. Since the coverage specifies that the drug was dropped as part of this review, observers will be monitoring whether other assets from the Kymab acquisition are similarly affected or if other shifts in the pharmaceutical portfolio are announced. While amlitelimab's path for atopic dermatitis has ended, the broader implications for Sanofi's strategic direction under new management remain a primary point of interest for industry analysts.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 114d ago.
Quick answers
What is the name of the drug Sanofi is dropping?
The drug is called amlitelimab, an OX40L antibody.
How much did Sanofi pay for the Kymab buyout?
Fierce Biotech reports the buyout was $1.1 billion, while BioSpace refers to it as a $1.4 billion bet.
Why was the drug shelved?
The decision followed a review of Sanofi's pipeline under the direction of a new CEO.
Coverage (5)
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped BioSpace · 117d ago
- Sanofi nixes Kymab-originated OX40L antibody in eczema Endpoints News · 117d ago
- Sanofi shelves amlitelimab in atopic dermatitis after pipeline review FirstWord Pharma · 117d ago
- Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO WSJ · 117d ago
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout Fierce Biotech · 117d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.